Interlude Biopharma Co.

Oklahoma Medical Research Foundation

9 Meters Biopharma, Inc.

Balasingham Radhakrishnan

Jay P Madan

Jay Madan

Sandeep Laumas

Kendyle Kennsengten

Umesh Deshmukh

Kathy L Sivils

Harini Bagavant

Christopher Prior

Gary F Musso

The present invention provides compositions and methods for treating Sjogren's syndrome (SS), including primary or secondary SS, as well as methods for preventing clinical disease in patients at risk of developing clinical SS. In various embodiments, the invention relates to administering a regimen of larazotide (or derivative) and/or 4-APAA compounds or 5-ASA compounds (e.g., 5-ASA, 4-ASA, 4-Ac APAA, and 4-APAA) to a patient in need thereof.

Compositions and methods for treating Sjogren's syndrome

The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.

Larazotide formulations

The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy and more desirable dosing schedules.

Compounds and methods for treating tight junction permeabtility

Growing community of inventors

Raleigh, NC, United States of America

Balasingham Radhakrishnan